Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).

Cancer Med · 2016 · PMC5055181 · PMID 27465221

Europe PMC DOI

hedged sentence

0.0680

closest p · 1.4× alpha

0.0680

boldest claim

The sentences

showed a trendP = 0.068so close (0.05 < p ≤ 0.1)

In the KRAS WT group, no association was observed between EGF and PFS ( P = 0.482), but EGF levels showed a trend toward being prognostic for OS (HR = 1.21, 95% CI = 0.99–1.49, P = 0.068).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.